Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors

Saikat Chowdhury, Joanne Xiu, Jennifer R. Ribeiro, Theodore Nicolaides, Jian Zhang, W. Michael Korn, Kelsey Poorman, Heinz‐Josef Lenz, John L. Marshall, Matthew J. Oberley, George W. Sledge, David Spetzler, Scott Kopetz, John Paul Shen